Background: The Kaiser Permanente early onset sepsis (EOS) calculator was introduced in 2016 for infants who were born at ≥35 weeks gestation or more (≥35GA) at a principal referral and specialist hospital for women and newborns in Western Australia to reduce unnecessary antibiotic administration in healthy neonates. Aim: The aim of this study was to determine the effect of the EOS calculator on antibiotic orders aseptically prepared by the pharmacy. Methods: The study retrospectively compared pharmacy data over two periods, before (2015) and after (2016) implementation. Results: After implementation, the number of gentamicin prefilled syringes (PFS) distributed decreased by 41.6% (1466 doses). In addition, the number of ≥35GA neonates receiving benzylpenicillin PFS decreased by 33.9% (222 neonates), and the overall rate (number of neonates receiving a benzylpenicillin PFS/occupied bed days) decreased from 2.24% to 1.48% (p < 0.0001).
INTRODUCTION
Early onset sepsis (EOS) in neonates is a serious and potentially life-threatening infection occurring in the first 72 hours of life. [1] [2] [3] It is most commonly caused by a Group B streptococcus (GBS) or Escherichia coli infection. [1] [2] [3] [4] The local clinical practice (King Edward Memorial Hospital (Women and Newborn Health Service)) for the identification and management of neonates at high risk of EOS was based on the Centers for Disease Control and Prevention (CDC) guidelines. 2 The guideline algorithm recommends the use of empirical antibiotic therapy based on signs and symptoms of neonatal sepsis, which can be non-sensitive, non-specific and clinician dependant. 1, 2, 5 Since the implementation of antenatal GBS screening and intrapartum antibiotic prophylaxis (IAP), the incidence of EOS has been reported to range between 0.4 and 1.2 cases per 1000 live births. [3] [4] [5] [6] [7] Despite the low incidence of EOS, the use of the CDC guidelines resulted in antibiotic exposure for many neonates without proven infection. 3, 5, 6 In a cohort of 7226 wellappearing infants with a gestational age (GA) of 35 weeks or more, Mukhopadhyay et al. 6 found that 588 infants (8%) were treated with empirical antibiotics but only three infants (0.04%) from the same cohort had blood culture-proven infections. This potentially unnecessary and/or prolonged administration of empirical antibiotic therapy may lead to adverse effects for the infant, antimicrobial resistance, disruption of the evolving neonatal intestinal microbiome, development of serious infections such as necrotising enterocolitis, reduced parent-infant time and increased risk of future health problems. [8] [9] [10] In addition, unnecessary antibiotic administration is associated with costs from stock acquisition, therapeutic drug monitoring, the time required for doctors and nurses to prescribe and administer the antibiotics, and an extended length of stay for neonates receiving treatment. In March 2016, the EOS calculator was introduced for use in infants who were who were born at ≥35 weeks gestation (≥35GA) at King Edward Memorial Hospital (KEMH), a principal referral and specialist hospital for women and newborns in Western Australia. This was followed by an extensive staff education period. The calculator was being fully exclusively used by 1 July 2016.
The primary objective of the present study was to determine the effect of the introduction of the EOS calculator on antibiotic orders prepared aseptically by the pharmacy.
METHODS
Benzylpenicillin and gentamicin are used as combination empirical antibiotic therapy for EOS at KEMH. The present study retrospectively compared antibiotic dispensing and distribution data over two 9-month periods in March-November 2015 (before implementation) and March-November 2016 (after implementation).
Benzylpenicillin prefilled syringes (PFS) data were obtained from the daily pharmacy Microsoft (Bellevue, WA, USA) Excel dispensing log. Gentamicin PFS were distributed as imprest items to the wards as either 25 mg/2.5 mL or 8 mg/0.8 mL. The gentamicin data were extracted from the pharmacy management software iPharmacy (CSC, NSW, Australia) and the monthly pharmacy Excel compounding log. The destruction log was used to exclude any expired and unused imprest gentamicin PFS.
Local (KEMH) neonatal occupied bed days (OBD) data were used as a denominator for rate calculations in order to take into account the overall hospital activity in the data analysis. This included data from the special care nurseries (SCN) and the infant cots in the obstetric wards. All neonates admitted to the obstetric wards were considered to be ≥35GA. Neonates admitted to the SCN were further subdivided into two categories of either <35 weeks GA or ≥35GA based on the hospital's electronic patient information database. The data for neonates of all gestational ages (ALL-GA) were also analysed to allow comparison with the target ≥35GA neonates.
Pre-and post-implementation data were analysed using Microsoft (Bellevue, WA, USA) Excel and Tableau software (Seattle, WA, USA). Proportional comparisons of the number of patients receiving benzylpenicillin per OBD were analysed using Chi-squared tests, whereas a two-sample Z-test was used to assess possible differences in the duration of benzylpenicillin therapy.
Ethics
This clinical audit was reviewed by the KEMH Research Screening Group and was deemed to not require full Human Research Ethics Committee review on the basis that it was a quality activity. The audit was entered into the Western Australian Health Governance, Evidence, Knowledge, Outcomes (GEKO) system (Quality Activity 13811).
RESULTS

Gentamicin Analysis: Imprest Distribution
After implementation of the EOS calculator, the number of neonatal gentamicin PFS distributed to the neonatal and obstetric wards within the audit period decreased by 41.6% (1466 doses).
Benzylpenicillin Analysis
Number of Neonates Receiving PFS
The number of target ≥35GA neonates receiving benzylpenicillin PFS decreased by 33.9%, from 654 neonates before implementation to 432 neonates after implementation ( Figure 1 ). The number of ALL-GA neonates receiving benzylpenicillin PFS decreased by 6.6%, from 968 neonates in the pre-implementation period to 904 neonates in the post-implementation period (Figure 1 ). Figure 1 Number of neonates receiving benzylpenicillin prefilled syringes (PFS) before and after implementation of the early onset sepsis calculator. There was a decrease in the number of neonates receiving benzylpenicillin PFS. ALL-GA, neonates of all gestational ages; ≥35GA, neonates born ≥35 weeks gestation.
Rate (Number of Neonates receiving PFS/OBD)
The overall rate (i.e. number of neonates receiving benzylpenicillin PFS/OBD) of the target ≥35GA neonates decreased from 2.24% (654/29 245) before implementation to 1.48% (432/29 115) after implementation (p < 0.0001; Figure 2 ). The overall rate of ALL-GA neonates receiving benzylpenicillin PFS did not decrease significantly, from 3.31% (968/29 245) before implementation to 3.1% (904/29 115) in the post-implementation period (p = 0.16; Figure 2 ). The monthly breakdown is shown in Figure 3 .
Number of Doses
The number of benzylpenicillin PFS doses administered to ≥35GA neonates decreased by 34.9% (918 doses) in the post-implementation period. The number of benzylpenicillin PFS doses administered to ALL-GA neonates decreased by 29.1% (1482 doses) in the postimplementation period.
Duration of Therapy
The mean duration of benzylpenicillin PFS for individual ALL-GA neonates did not change from the pre-implementation to the post-implementation period (2.6 days AE 1.2 vs 2.5 days AE 1.1 days, respectively; p = 0.115). The number of doses per ALL-GA neonates decreased by 24.5%, from 5.3 doses per neonate in the pre-implementation period to 4 doses per neonate in the postimplementation period. The number of doses per ≥35GA neonate was similar in both periods: 4 doses per neonate before implementation and 3.9 doses per neonate after implementation.
These results are expected because the EOS calculator was not designed to determine the duration of empirical antibiotic therapy.
DISCUSSION
The present study has demonstrated that the introduction of the Kaiser Permanente EOS calculator has reduced the number and rate of target ≥35GA neonates receiving pharmacy-prepared empirical antibiotics at KEMH based on the benzylpenicillin PFS data. There was also an overall reducing trend in ALL-GA neonates in the audit period based on both benzylpenicillin and gentamicin PFS data.
Although the EOS calculator was originally developed for infants born at 34 weeks gestation, because this cohort is routinely admitted to the neonatal intensive care unit (NICU) for closer monitoring at KEMH, the hospital introduced the use of the calculator for ≥35GA, a practice consistent with and recently validated by the original investigators. Figure 2 Overall rate (i.e. number of neonates receiving benzylpenicillin prefilled syringes (PFS)/occupied bed days) before and after implementation of the early onset sepsis calculator. Although there was a decrease in the overall rate in both groups, only the decrease in the neonates ≥35 weeks gestational age (≥35GA) was significant (p < 0.0001). ALL-GA = neonates of all gestational ages. 
No. neonates/OBD (%)
ALL-GA before implementation ≥35GA before implementation ≥35GA after implementation ALL-GA after implementation Figure 3 Monthly breakdown of the rate of neonates receiving benzylpenicillin prefilled syringes (PFS), calculated as the number of neonates/occupied bed days (OBD), before and after implementation of the early onset sepsis calculator. ALL-GA = neonates of all gestational ages; ≥35GA, neonates born ≥35 weeks gestation.
Limitations of the present study include the sole inclusion of data specific to empirical antibiotics aseptically prepared by the pharmacy. The effect of the calculator is most probably underestimated considering that data regarding empirical antibiotics prepared in the wards were not included. The recent retrospective study of 204 485 neonates by Kuzniewicz et al. 12 found that the EOS calculator decreased the number of empirical antibiotics administered by 48%, without any increase in delayed antibiotic use, readmission rates due to EOS and other adverse clinical effects. At KEMH, adverse clinical outcomes were not observed in neonates with a low calculated risk estimate score following the use of the calculator throughout the study period. However, the present study focused on prescribing rates and was not designed to assess the range of EOS scores recorded or to objectively assess clinical outcomes. In an area such as neonatal care, where the risks of undertreatment of EOS can be catastrophic, a more structured and objective clinical approach to review would be an important area for research and should include the analysis of antibiotic prescriptions in the first 24 hours of a neonate's life, the average time between birth and the first antibiotic dose, the rate of hospital readmission due to sepsis or positive culture and the rate of complications as a result of delayed antibiotic administration.
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CONCLUSION
The introduction of the neonatal EOS calculator has reduced the number and rate of prescription of pharmacy-prepared empirical antibiotics in neonates of the target GA of ≥35 weeks at KEMH.
